Evidence map›Paper›PMID 33456463›Full record

ArticleJournal of oncology2020

Identification of a Prognostic Risk Signature of Kidney Renal Clear Cell Carcinoma Based on Regulating the Immune Response Pathway Exploration.

Guangzhen Wu, Yingkun Xu, Chenglin Han, Zilong Wang, Jiayi Li, Qifei Wang, Xiangyu Che

Open access · hybridAbstract read
In one paragraph

Article in Journal of oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Guangzhen WuDepartment of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.ORCID https://orcid.org/0000-0002-2300-8465
Yingkun XuDepartment of Urology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.ORCID https://orcid.org/0000-0002-0100-9117
Chenglin HanDepartment of Urology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.ORCID https://orcid.org/0000-0003-0757-8692
Zilong WangDepartment of Urology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.ORCID https://orcid.org/0000-0001-8700-8299
Jiayi LiSchool of Business, Hanyang University, Seoul, Republic of Korea.
Qifei WangDepartment of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.ORCID https://orcid.org/0000-0002-9365-0373
Xiangyu CheDepartment of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.ORCID https://orcid.org/0000-0003-4646-1390
Dalian Medical University · CNShandong University · CNHanyang University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo construct a survival model for predicting the prognosis of patients with kidney renal clear cell carcinoma (KIRC) based on gene expression related to immune response regulation. MATERIALS AND

methodsKIRC mRNA sequencing data and patient clinical data were downloaded from the TCGA database. The pathways and genes involved in the regulation of the immune response were identified from the GSEA database. A single factor Cox analysis was used to determine the association of mRNA in relation to patient prognosis (

resultsCompared with normal kidney tissues, there were 28 dysregulated mRNA expressions in KIRC tissues (

conclusionWe constructed a risk prediction model based on the regulated immune response-related genes, which can effectively predict the survival of patients with KIRC.

Identifiers

PMID33456463
PMCPMC7787716
OpenAlexW3115784919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.